FOLD
Income statement / Annual
Last year (2023), Amicus Therapeutics, Inc.'s total revenue was $399.36 M,
an increase of 21.30% from the previous year.
In 2023, Amicus Therapeutics, Inc.'s net income was -$151.58 M.
See Amicus Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$399.36 M
|
$329.23 M
|
$305.51 M
|
$260.89 M
|
$182.24 M
|
$91.25 M
|
$36.93 M
|
$4.96 M
|
$0.00
|
$1.22 M
|
| Cost of Revenue |
$45.20 M |
$38.60 M |
$34.47 M |
$31.04 M |
$21.96 M |
$14.40 M |
$6.24 M |
$833,000.00 |
$1.83 M |
$0.00 |
| Gross Profit |
$354.16 M |
$290.63 M |
$271.05 M |
$229.84 M |
$160.27 M |
$76.84 M |
$30.69 M |
$4.13 M |
-$1.83 M |
$1.22 M |
| Gross Profit Ratio |
0.89 |
0.88 |
0.89 |
0.88 |
0.88 |
0.84 |
0.83 |
0.83 |
0 |
1 |
| Research and Development
Expenses |
$152.38 M
|
$276.68 M
|
$272.05 M
|
$308.44 M
|
$286.38 M
|
$270.90 M
|
$149.31 M
|
$104.79 M
|
$76.94 M
|
$47.62 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$127.20 M
|
$0.00
|
$71.15 M
|
$47.27 M
|
$20.72 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$275.27 M
|
$213.04 M
|
$192.71 M
|
$156.41 M
|
$169.86 M
|
$127.20 M
|
$88.67 M
|
$71.15 M
|
$47.27 M
|
$20.72 M
|
| Other Expenses |
-$15.89 M |
$5.34 M |
$6.21 M |
$8.85 M |
$4.78 M |
-$5.63 M |
$6.01 M |
-$4.79 M |
-$80,000.00 |
-$77,000.00 |
| Operating Expenses |
$427.65 M |
$495.06 M |
$470.97 M |
$473.70 M |
$461.01 M |
$402.32 M |
$241.57 M |
$179.19 M |
$126.05 M |
$69.89 M |
| Cost And Expenses |
$472.85 M |
$533.66 M |
$505.43 M |
$504.74 M |
$482.98 M |
$416.72 M |
$247.81 M |
$180.02 M |
$126.05 M |
$69.89 M |
| Interest Income |
$7.08 M |
$3.02 M |
$509,000.00 |
$3.23 M |
$10.25 M |
$10.46 M |
$4.10 M |
$1.60 M |
$929,000.00 |
$223,000.00 |
| Interest Expense |
$50.15 M |
$37.12 M |
$32.47 M |
$22.43 M |
$18.87 M |
$22.40 M |
$17.24 M |
$5.40 M |
$1.58 M |
$1.48 M |
| Depreciation &
Amortization |
$7.87 M
|
$5.34 M
|
$6.21 M
|
$8.85 M
|
$4.78 M
|
$4.22 M
|
$3.59 M
|
$3.24 M
|
$1.83 M
|
$1.55 M
|
| EBITDA |
-$65.62 M
|
-$191.88 M
|
-$196.10 M
|
-$232.56 M
|
-$328.97 M
|
-$316.43 M
|
-$197.18 M
|
-$175.01 M
|
-$123.36 M
|
-$66.97 M
|
| EBITDA Ratio |
-0.16 |
-0.58 |
-0.64 |
-0.89 |
-1.81 |
-3.47 |
-5.34 |
-35.3 |
0 |
-54.71 |
| Operating Income Ratio
|
-0.18
|
-0.62
|
-0.65
|
-0.93
|
-1.65
|
-3.6
|
-11.97
|
-36.69
|
0
|
-56.13
|
| Total Other
Income/Expenses Net |
-$76.61 M
|
-$37.61 M
|
-$41.63 M
|
-$30.40 M
|
-$55.17 M
|
-$11.67 M
|
-$225.10 M
|
-$24.92 M
|
-$5.42 M
|
-$114,000.00
|
| Income Before Tax |
-$150.10 M |
-$242.04 M |
-$241.55 M |
-$274.25 M |
-$355.91 M |
-$349.09 M |
-$449.12 M |
-$203.78 M |
-$132.12 M |
-$70.04 M |
| Income Before Tax Ratio
|
-0.38
|
-0.74
|
-0.79
|
-1.05
|
-1.95
|
-3.83
|
-12.16
|
-41.1
|
0
|
-57.22
|
| Income Tax Expense |
$1.48 M |
-$5.47 M |
$8.91 M |
$2.60 M |
$478,000.00 |
-$94,000.00 |
-$165.12 M |
-$3.74 M |
$1.50 M |
-$1.11 M |
| Net Income |
-$151.58 M |
-$236.57 M |
-$250.46 M |
-$276.85 M |
-$356.39 M |
-$349.00 M |
-$284.00 M |
-$200.04 M |
-$132.12 M |
-$68.93 M |
| Net Income Ratio |
-0.38 |
-0.72 |
-0.82 |
-1.06 |
-1.96 |
-3.82 |
-7.69 |
-40.35 |
0 |
-56.31 |
| EPS |
-0.51 |
-0.82 |
-0.92 |
-1.07 |
-1.48 |
-1.88 |
-1.85 |
-1.49 |
-1.2 |
-0.93 |
| EPS Diluted |
-0.51 |
-0.82 |
-0.92 |
-1.07 |
-1.48 |
-1.88 |
-1.85 |
-1.49 |
-1.2 |
-0.93 |
| Weighted Average Shares
Out |
$295.16 M
|
$289.06 M
|
$271.42 M
|
$258.87 M
|
$240.42 M
|
$185.79 M
|
$153.36 M
|
$134.40 M
|
$109.92 M
|
$74.44 M
|
| Weighted Average Shares
Out Diluted |
$295.16 M
|
$289.06 M
|
$271.42 M
|
$258.87 M
|
$240.42 M
|
$185.79 M
|
$153.36 M
|
$134.40 M
|
$109.92 M
|
$74.44 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
